Pasithea Therapeutics (KTTAW) Competitors $0.01 0.00 (-9.09%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock KTTAW vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech Aravive Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity 180 Life Sciences (NASDAQ:ATNFW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Does the media refer more to ATNFW or KTTAW? In the previous week, 180 Life Sciences had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.91 beat 180 Life Sciences' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Pasithea Therapeutics Very Positive Which has better valuation and earnings, ATNFW or KTTAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/APasithea TherapeuticsN/AN/AN/AN/AN/A Is ATNFW or KTTAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Pasithea Therapeutics N/A N/A N/A Summary180 Life Sciences and Pasithea Therapeutics tied by winning 1 of the 2 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTAW vs. The Competition Export to ExcelMetricPasithea TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$222.30M$6.08B$10.54BDividend YieldN/A3.80%5.73%4.78%P/E RatioN/A100.3884.6327.10Price / SalesN/A5,842.96605.70131.13Price / CashN/A13.1937.8662.13Price / BookN/A97.5312.246.58Net IncomeN/A-$90.99M$3.32B$276.75M7 Day PerformanceN/A0.73%0.76%0.92%1 Month PerformanceN/A6.07%8.03%4.21%1 Year PerformanceN/A682.81%71.14%37.89% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAWPasithea TherapeuticsN/A$0.01-9.1%N/A-61.0%$0.00N/A0.003Positive NewsATNFW180 Life SciencesN/A$0.06+3.3%N/A+172.9%$0.00N/A0.007News CoverageGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.21-22.2%N/AN/A$0.00$110.87K0.0040Positive NewsGap UpALVOWAlvotechN/A$1.75+17.4%N/A-51.8%$0.00$560.10M0.004Positive NewsGap UpHigh Trading VolumeARAVAraviveN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03+2.0%N/A+15.3%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.10-1.8%N/A+214.5%$0.00$39.19M0.0070Positive NewsBTMDWbioteN/A$0.01-6.6%N/A-98.7%$0.00$199.07M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.06+16.2%N/A-82.1%$0.00N/A0.008Short Interest ↑Gap DownHigh Trading VolumeCELUWCelularityN/A$0.03-5.1%N/A+133.8%$0.00$44.59M0.00220Positive NewsShort Interest ↓ Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Ainos Alternatives Alvotech Alternatives Aravive Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Celularity Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTAW) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
